Deucravacitinib (Deucrava) is not a biologic; it is a small molecule. Specifically, deucravacitinib is an oral Janus kinase (JAK) inhibitor. It works by inhibiting specific enzymes involved in the inflammatory process, and it is used in the treatment of certain autoimmune diseases, such as psoriasis and rheumatoid arthritis.
Biologics, on the other hand, are large, complex molecules typically produced using living cells. They include monoclonal antibodies and other proteins that target specific components of the immune system. Deucravacitinib belongs to a different class of drugs known as small molecules, which are chemically synthesized and have a smaller molecular size compared to biologics.
Please note that developments in the pharmaceutical field occur, and new information may emerge. For the most up-to-date and accurate information about deucravacitinib, its classification, and its current status, it is recommended to consult recent medical literature, healthcare professionals, or reliable sources.
What is deucravacitinib approved for?
deucravacitinib had not yet received approval from regulatory authorities for clinical use. At that time, deucravacitinib was still in the experimental or investigational stage. Particularly in clinical trials for conditions such as moderate to severe plaque psoriasis.
Clinical trials are conducted to evaluate the safety and efficacy of new medications before they can be approved for widespread use. Since developments in the pharmaceutical field can occur, it’s important to check more recent and reliable sources, such as regulatory agencies, official prescribing information, or medical literature, to determine if deucravacitinib has received approval for specific indications since my last update in January 2022. If there have been updates or changes, this information should be available from sources that provide the latest information on drug approvals and usage.
What is deucravacitinib indicated to treat?
Deucravacitinib was still in the investigational stage, and it had not yet received regulatory approval for clinical use. Therefore, there were no officially approved indications for deucravacitinib at that time.
Deucravacitinib has been primarily studied in clinical trials for the treatment of autoimmune conditions, particularly moderate to severe plaque psoriasis. Psoriasis is a chronic skin disorder characterized by the rapid turnover of skin cells, leading to the formation of thick, red, and scaly patches.
For the most up-to-date and accurate information regarding deucravacitinib and its indications, it is recommended to consult more recent sources, such as regulatory agencies, official prescribing information, or medical literature.
What is another name for Deucravacitinib (Deucrava)?
The brand name for Deucravacitinib (Deucrava) is Sotyktu. It is a first-in-class oral tyrosine kinase 2 (TYK2) inhibitor that is used to treat moderate-to-severe plaque psoriasis.
Other names for deucravacitinib include:
- BMS-986165
- TYK2 inhibitor
- JAK1/TYK2 inhibitor
- TYK2 selective inhibitor
- Allosteric TYK2 inhibitor
Deucravacitinib (Deucrava) was approved by the US Food and Drug Administration (FDA) in September 2022 and the European Medicines Agency (EMA) in March 2023. It is a promising new treatment for psoriasis, and it is still under investigation for other inflammatory conditions.
What class of drug is Deucravacitinib (Deucrava)?
Deucravacitinib (Deucrava) is a Janus kinase (JAK) inhibitor. The JAK inhibitors are a class of medications that target Janus kinases. Enzymes that play a role in the signaling pathways involved in inflammation and immune responses. By inhibiting these enzymes, JAK inhibitors modulate the immune system and are used in the treatment of autoimmune diseases. such as rheumatoid arthritis and psoriasis. Deucravacitinib, as a JAK inhibitor, is designed to interfere with these signaling pathways. Deucravacitinib (Deucrava) may be used in the treatment of autoimmune conditions.
When was deucravacitinib FDA approved?
Deucravacitinib was FDA approved on September 9, 2022, for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
It is the first FDA-approved oral TYK2 inhibitor for plaque psoriasis. TYK2 is a protein that plays a role in the inflammation that causes psoriasis. By inhibiting TYK2, deucravacitinib can help to reduce inflammation and improve skin clearance.
Deucravacitinib is a promising new treatment for psoriasis, and it is still under investigation for other inflammatory conditions, such as psoriatic arthritis, inflammatory bowel disease, and lupus.
